
PRAMIS

Background

- Essential tremor (ET) is the most common movement disorder, with high unmet patient needs.¹
- ET is characterized by involuntary progressive tremor especially in the hands and upper limb, contributing to patient disability.^{2,3}
- Existing treatment options are limited, with high discontinuation rates due to poor tolerability and modest efficacy.⁴
- Mounting evidence points to increased neuronal burst firing and oscillations in cerebello-thalamo-cortical (CTC) circuitry as main drivers of tremor, with modulation of CTC neuronal burst firing patterns thought to be dependent on T-type Ca²⁺ channel activity.⁵⁻⁸
- PRAX-944 is a novel, selective T-type Ca²⁺ channel blocker in clinical development for ET treatment.^{9,10}
- We present results from PRAX-944-221, a Phase 2 clinical trial evaluating efficacy, safety, tolerability, and pharmacokinetics of PRAX-944 in adults with ET.


Methods

- PRAX-944-221 was a 2-part trial focused on adult patients (≥18 years) with ET.
- Trial registration: clinicaltrials.gov (NCT05021978)
- Part A: Open label
- PRAX-944 20 mg administered orally every morning for 7 days followed by 40 mg every morning for 7 days • Eligible participants were receiving either no medications or 1 stable dose tremor medication, excluding
- primidone. • Primary outcome: change from baseline in upper limb tremor assessed by The Essential Tremor Rating
- Assessment Scale (TETRAS-UL). • Secondary outcomes included change from baseline in measures of tremor severity assessed by The
- Essential Tremor Rating Performance Scale (TETRAS-PS), as well as safety and tolerability measures.
- Mean change from baseline in TETRAS scores were transformed using Weber-Fechner equations to calculate percent changes in tremor amplitude.¹¹
- Part B: Open-label titration followed by randomized, double-blind, placebo-controlled withdrawal
- Daily dose levels were titrated from 20 mg up to 120 mg during the open-label phase with at least 14 days of dosing at the highest tolerated dose for each participant.
- In the randomized, double-blind, placebo-controlled withdrawal phase, participants were either maintained on their final open-label dose or switched to placebo for 14 days.
- Primary outcome: safety and tolerability; secondary outcomes included TETRAS-UL and other measures of disease impact including accelerometry, TETRAS-PS and TETRAS activities of daily living (TETRAS-ADL).
- Presented here are accelerometry-based TETRAS-UL findings and exploratory efficacy analyses involving modified ADLs, derived based on selected clinician measured TETRAS-ADL and TETRAS-PS item scores.



References

- Louis and Ottman. 2014 *Tremor Other Hyperkinet Mov (NY)*
- 2. Chen et al. 2017 *Transl Neurodegener*
- Lageman et al. 2014 *Tremor Other Hyperkinet Mov (NY)*
- 4. Louis, Rios and Henchcliffe. 2010 Eur J Neurol
- 5. Pinto, Lang and Chen. 2003 Neurology
- 6. Park, Kim and Kim. 2013 Front Neural Circuits
- 7. Powell et al. 2014 Br J Pharmacol
- 8. Kondylis et al. 2016 Brain



PATHOLOGICAL

A Phase 2 Clinical Trial Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of PRAX-944 in Adults with Essential Tremor



9. Scott et al. 2022 Mov Disord 10. Belfort et al. 2022 AAN Annual Meeting 11. Elble. 2018 Tremor Other Hyperkinet Mov

assistance were provided by Lillian G. Matthews and Kathleen Pillsbury Hopf in accordance with Good Publication Practice (GPP3) guidelines.

Disclosures All authors are current or former employees/consultants of Praxis Precision Medicines and may be Praxis stockholders.

clinicaltrials@praxismedicines.com

Omar Olhaye¹, Gabriel Belfort¹, Shane Raines¹, Ted Snyder¹, Bernard Ravina¹ ¹Praxis Precision Medicines, Boston, MA 02110 USA

Part B: Functional Benefits Observed on Treatment


• Eleven of 14 evaluable patients completed both open-label and randomized withdrawal (6 PRAX-944, 5 placebo) phases.

• Marked functional benefit was observed on treatment with PRAX-944, with withdrawal resulting in regression to baseline severity (*Fig. 3 and 4*). • The observed functional benefit from PRAX-944 was supported by tremor analyses (*Fig. 5 and 6*).

• Spiral task drawings demonstrating the impact of PRAX-944 on ability to draw during the open-label and withdrawal phases are shown in *Fig. 7.*

Figure 3. Modified ADLs in open label: *mean % change from baseline*

Figure 4. Modified ADLs in randomized withdrawal: mean % change from Day 42



The modified ADL is a composite sum of items 1 to 11 of the TETRAS-ADL subscale and items 6 and 7 on the TETRAS-PS

Figure 5. Kinesia One in open label:





Figure 6. Kinesia One in randomized withdrawal: mean % change from Day 42



Kinesia One assessments are based on TETRAS-UL tasks performed by participants while wearing a Kinesia One accelerometer

Figure 7. Example of spiral task (item 6 of TETRAS-PS) from Part B patient





Presented at: International Congress of Parkinson's **Disease and Movement Disorders**[®] 2022 Meeting September 15-18, 2022 Madrid, Spain